DGX - Conference and earnings call announcements

USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Feb. 19, 2025 /PRNewswire/ -- USA News Group News Commentary – Amid the excitement surrounding Project Stargate—the $500 billion investment aimed at revolutionizing AI-driven data centers—concerns over the rising global cancer rates, particularly among younger populations, remain pressing. Lifestyle factors are increasingly under scrutiny, with the World Health Organization (WHO) now advocating for cancer warning labels on alcohol products. Despite these alarming trends, several biotech companies have already made notable strides in 2025, with recent advancements coming from Oncolytics Biotech Inc. (NASD

Toronto, Ontario, July 10, 2023 (GLOBE NEWSWIRE) -- A new analysis of more than 460 million lipid test results of patients living in 17 countries on five continents provides new evidence that where a person lives and their sex influence their risk of cardiovascular disease, possibly due in part to differences in genetics, lipid testing, lifestyle habits, and pharmacologic treatment. Performed by researchers from Johns Hopkins University, Quest Diagnostics (NYSE:DGX), LifeLabs and seven other laboratories participating in the Quest-led Global Diagnostics Network (GDN), the analysis is believed to be the largest ever to evaluate worldwide variability in lipid levels. The analysis finds th

SECAUCUS, N.J., Sept. 9, 2021 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:DGX), the world's leading provider of diagnostic information services, today updated its financial outlook for full year 2021. Since the company reported its financial performance for the second quarter of 2021 on July 22, 2021, COVID-19 molecular testing volumes were stronger than anticipated through the end of August and are expected to continue to be stronger than anticipated because of the surge of the Delta variant. The low end of the company's outlook now assumes average COVID-19 volumes

NEWARK, Del., July 20, 2021 /PRNewswire/ -- CLX Health, developer of cloud-based solutions to manage the COVID-19 testing ecosystem with their TrustAssure™ Global Network, today announced a collaboration with Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, to provide access to COVID-19 molecular diagnostic testing (PCR/NAAT) for people seeking to attend live events nationwide or travel from the United States to destinations around the world. Though the TrustAssure™ Global Testing Platform, individuals will be able to schedule appointments for molecular COVID-19 tests at select Quest Diagnostics patient service centers and more than 750 retail pa

SECAUCUS, N.J., May 26, 2021 /PRNewswire/ -- The COVID-19 pandemic did not dampen workforce drug testing positivity for marijuana, which continued to increase last year in the general U.S. workforce, according to a new analysis released today by Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services. This study is thought to be the first large-scale analysis of de-identified results of laboratory workforce drug tests performed during the COVID-19 pandemic. The overall positivity rate in the combined U.S. workforce based on more than

SECAUCUS, N.J., Feb. 16, 2021 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at Citi's 2021 Healthcare Services, Medtech, Tools, & HCIT Virtual Conference.  Mark Guinan, Executive Vice President & CFO will discuss the company's vision, goals, and capital deployment strategies.  The presentation is scheduled for Wednesday, February 24, 2021 at 1:30 p.m. Eastern Time. The presentation will be webcast live during the conference and will be available on the company's investor relations page which can be accessed at ir.QuestDiagnostics.com.  In addition, the archived webcast w